All colloquium talks for the 2025-2026 academic year will be held in the Sir Henry Wellcome Building room G17 (also online) from 3:30pm-5pm unless specified otherwise.
Please to continue to refer back to this page for any updates regarding colloquium timetabling and speaker information.
Dr Henry Fisher is the Chief Scientific Officer and Co-founder of Clerkenwell Health, a CRO and clinical research site network specialising in psychiatry and CNS research, with a core focus on clinical trials with psychedelics. He leads on trial design, regulator engagement, clinical development advisory services and controlled drug licensing compliance. He holds a DPhil from Oxford in Pharmaceutical Chemistry. Formerly, he has worked for Volteface drug policy think tank, The Beckley Foundation and The Loop. Since then Henry has founded three companies in the psychedelics and cannabis sectors and advised clients on R&D strategies, IP generation and research operations.
Yogi Hale Hendlin is an environmental philosopher and public health scientist. Currently Assistant Professor of Philosophy and member of the Dynamics of Inclusive Prosperity Initiative at Erasmus University Rotterdam, Hendlin is also a member of the The Center to End Corporate Harm at the University of California, San Francisco, and Principal of the Feral Ecologies Lab. Editor-in-Chief of the journal Biosemiotics, Hendlin is also editor of two books (Food and Medicine: A Biosemiotic Perspective and Being Algae: Transformations in Water, Plants). Hendlin’s work investigates ecologies of meaning, and takes seriously the implications of 5EA cognitive science that experience is distributed throughout many dimensions and emerges ecologically as an outside-in affair.
Mourad is a Consultant Psychiatrist and Lead Clinician for the Care Pathway Enhancement (CaPE) Clinic, a specialist mood disorder research clinic within the Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust. Clinically, he works in the space between primary and secondary care, supporting people with mood disorders across a wide range of complexity. Academically, his focus is on novel and emerging treatments, with a particular interest in psychedelic therapy.